

RESEARCH SEMINAR SERIES

# PK considerations for the use of long-acting antiretrovirals during pregnancy

---

**January 8, 2025 | 12:00 pm – 12:50 pm**

050 Apotex Centre, Bannatyne Campus



## **Dr. Adeniyi Olagunju**

Department of Biochemistry, Cell, and Systems Biology  
University of Liverpool

**Dr Adeniyi Olagunju** is a Senior Lecturer in the Department of Biochemistry, Cell and Systems Biology and a member of the Centre of Excellence for Long-acting Therapeutics (CELT), University of Liverpool. He leads the Perinatal Pharmacology Group where research is focused on broadening our understanding of drug safety and efficacy during pregnancy and lactation. Working across three domains (human-relevant in vitro modelling, in silico modelling and clinical research), Dr Olagunju's vision for his research programme is to transform the assessment of drug safety during pregnancy by developing a platform that will generate human pregnancy-relevant safety information early in drug development. This will facilitate decisions about safe inclusion of pregnant women in early-phase clinical trials, enabling evidence-based, pregnancy-specific recommendations for potentially life-saving therapeutics. His research is primarily funded by the Wellcome Trust.